Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Mizuho Remains Bullish On CMS Energy Amid Natural Gas Rate Case; Trims Price Target

By Nabaparna Bhattacharya

April 19, 1:26 PM

Mizuho analyst Anthony Crowdell reiterated a Buy rating on CMS Energy Corporation (NYSE:CMS), lowering the price target to $68 from $69. CMS…

CMS

Cathie Wood, Unfazed By SEC Lawsuit, Picks Up A Whopping $21M Stake In Coinbase Even As Stock Tanked 12%

By Bhavik Nair

June 6, 9:58 PM

Cathie Wood-led ARK Investment Management bought a whopping stake in Coinbase Global Inc (NASDAQ:COIN) on Tuesday â€“ a…

ARKF

Tesla Unveils Bold Electric Vision: 6 New EV Models And 250K Sales In Europe By 2026

By Anan Ashraf

December 4, 5:05 AM

In Europe, Toyota's electrified mix is already at 71% and is expected to grow to 75% in 2024

Elon Musk’s ‘Golden Child’ Tesla At Crossroads, Rivian Flags Spending Cut, Lucid Strikes Funding Deals And More: Week’s Biggest EV Stories

By Shanthi Rexaline

November 12, 9:41 AM

Electric vehicle stocks meandered to a mixed close in the week ending Nov. 11, with earnings news and the broader market sentiment serving as catalysts. Tesla, Inc.

AAPL

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Mizuho Remains Bullish On CMS Energy Amid Natural Gas Rate Case; Trims Price Target

Cathie Wood, Unfazed By SEC Lawsuit, Picks Up A Whopping $21M Stake In Coinbase Even As Stock Tanked 12%

Tesla Unveils Bold Electric Vision: 6 New EV Models And 250K Sales In Europe By 2026

Elon Musk’s ‘Golden Child’ Tesla At Crossroads, Rivian Flags Spending Cut, Lucid Strikes Funding Deals And More: Week’s Biggest EV Stories